Patents by Inventor Ronnie C. Mease
Ronnie C. Mease has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
Publication number: 20150246144
Abstract: The prostate-specific membrane antigen (PSMA) is increasingly recognized as a viable target for imaging and therapy of cancer. Various 99mTc/Re-labeled compounds were prepared by attaching known Tc/Re chelating agents to an amino-functionalized PSMA inhibitor with or without a variable length linker moiety. Ex vivo biodistribution and in vivo imaging demonstrated the degree of specific binding to engineered PSMA+PC3 PIP tumors.
Type: Application
Filed: May 18, 2015
Publication date: September 3, 2015
Applicant: THE JOHNS HOPKINS UNIVERSITY
Inventors: MARTIN G. POMPER, SANGEETA RAY, RONNIE C. MEASE, CATHERINE ANNE FOSS
-
Patent number: 9044468Abstract: The prostate-specific membrane antigen (PSMA) is increasingly recognized as a viable target for imaging and therapy of cancer. Various 99mTc/Re-labeled compounds were prepared by attaching known Tc/Re chelating agents to an amino-functionalized PSMA inhibitor with or without a variable length linker moiety. Ex vivo biodistribution and in vivo imaging demonstrated the degree of specific binding to engineered PSMA+ PC3 PIP tumors.Type: GrantFiled: June 26, 2008Date of Patent: June 2, 2015Assignee: THE JOHNS HOPKINS UNIVERSITYInventors: Martin G. Pomper, Ray Sangeeta, Ronnie C. Mease, Catherine Foss
-
Publication number: 20150104387Abstract: Prostate-specific membrane antigen (PSMA) targeting compounds are described. Uses of the compounds for imaging, therapy, cell sorting, and tumor mapping are also described.Type: ApplicationFiled: April 2, 2014Publication date: April 16, 2015Applicant: THE JOHNS HOPKINS UNIVERSITYInventors: MARTIN G. POMPER, RONNIE C. MEASE, YING CHEN, Sangeeta Ray
-
Publication number: 20140341804Abstract: The present invention provides bivalent and multivalent ligands with a view to improving the affinity and pharmacokinetic properties of a urea class of PSMA inhibitors. The compounds and their synthesis can be generalized to multivalent compounds of other target antigens. Because they present multiple copies of the pharmacophore, multivalent ligands can bind to receptors with high avidity and affinity, thereby serving as powerful inhibitors. The modular multivalent scaffolds of the present invention, in one or more embodiments, contains a lysine-based (?-, ?-)dialkyne residue for incorporating two or more antigen binding moieties, such as PSMA binding Lys-Glu urea moieties, exploiting click chemistry and one or more additional lysine residues for subsequent modification with an imaging and/or therapeutic nuclides or a cytotoxic ligands for tumor cell killing.Type: ApplicationFiled: November 30, 2012Publication date: November 20, 2014Applicant: THE JOHNS HOPKINS UNIVERSITYInventors: Martin Gilbert Pomper, Sangeeta Ray, Ronnie C. Mease
-
Publication number: 20110200677Abstract: The invention provides a nanoparticle composition that is decorated with a urea-based small-molecule peptidomimetic inhibitor of prostate specific membrane antigen (PSMA), which is expressed by almost all solid tumors. This strategy takes advantage of both the avidity of the functionalized nanoparticle for binding to PSMA and the ability of the nanoparticle to be retained for longer periods of time in the tumor due to enhanced leakage via EPR into the tumor interstitium and poor clearance due to underdeveloped or non-existent lymphatics within the tumor.Type: ApplicationFiled: November 26, 2008Publication date: August 18, 2011Applicant: THE JOHNS HOPKINS UNIVERSITYInventors: Sachin S. Chandran, Sangeeta Ray, Martin G. Pomper, Samuel R. Denmeade, Ronnie C. Mease
-
Publication number: 20110064657Abstract: The prostate-specific membrane antigen (PSMA) is increasingly recognized as a viable target for imaging and therapy of cancer. Various 99mTc/Re-labeled compounds were prepared by attaching known Tc/Re chelating agents to an amino-functionalized PSMA inhibitor with or without a variable length linker moiety. Ex vivo biodistribution and in vivo imaging demonstrated the degree of specific binding to engineered PSMA+ PC3 PIP tumors.Type: ApplicationFiled: June 26, 2008Publication date: March 17, 2011Applicant: The Johns Hopkins UniversityInventors: Martin Gilbert Pomper, Ray Sangeeta, Ronnie C. Mease, Catherine Foss
-
Patent number: 6022522Abstract: Bicyclo[2.2.2]octane-2,3 diamine-N,N,N’,N’-tetraacetic acids (BODTA) and bicyclo[2.2.1]heptane-2,3 diamine-N,N,N’,N’-tetraacetic acid (BHDTA) are chelating agents useful in forming detectably labeled bioconjugate compounds for diagnostic and therapeutic purposes. New compounds and processes of forming BODTA and BHDTA are disclosed. Radioimmunoconjugates of the present invention show high and prolonged tumor uptake with low normal tissue uptakes.Type: GrantFiled: March 23, 1998Date of Patent: February 8, 2000Assignee: Brookhaven Science AssociatesInventors: Mark P. Sweet, Ronnie C. Mease, Suresh C. Srivastava
-
Patent number: 5840859Abstract: A compound is provided of formula I: ##STR1## wherein n is 4-16, Det is an organic group comprising a radioisotope or capable of chelating a radioisotope, and Z.sup.- is one equivalent of a biologically acceptable anion, which compounds are useful to radiolabel cellular membranes, as of hematopoietic cells.Type: GrantFiled: June 27, 1996Date of Patent: November 24, 1998Assignee: Research Corporation Technologies, Inc.Inventors: Carol Lambert, Ronnie C. Mease, John G. McAfee
-
Patent number: 5783169Abstract: Bicyclo?2.2.2! octane-2,3 diamine-N,N,N’,N’-tetraacetic acids (BODTA) and bicyclo?2.2.1! heptane-2,3 diamine-N,N,N’,N’-tetraacetic acid (BHDTA) are chelating agents useful in forming detectably labeled bioconjugate compounds for diagnostic and therapeutic purposes. New compounds and processes of forming BODTA and BHDTA are disclosed. Radioimmunoconjugates of the present invention show high and prolonged tumor uptake with low normal tissue uptakes.Type: GrantFiled: July 26, 1995Date of Patent: July 21, 1998Assignee: Brookhaven Science Associates LLCInventors: Mark P. Sweet, Ronnie C. Mease, Suresh C. Srivastava
-
Patent number: 5639879Abstract: A simple method for the synthesis of 1,4,7, 10-tetraazacyclododecane N,N’N”,N'”-tetraacetic acid and 1,4,8,11-tetraazacyclotetradecane N,N’,N”,N'”-tetraacetic acid involves cyanomethylating 1,4,7, 10-tetraazacyclododecane or 1,4,8,11-tetraazacyclotetradecane to form a tetranitrile and hydrolyzing the tetranitrile. These macrocyclic compounds are functionalized through one of the carboxylates and then conjugated to various biological molecules including monoclonal antibodies. The resulting conjugated molecules are labeled with radiometals for SPECT and PET imaging and for radiotherapy.Type: GrantFiled: February 2, 1995Date of Patent: June 17, 1997Assignee: Associated Universities, Inc.Inventors: Ronnie C. Mease, Leonard F. Mausner, Suresh C. Srivastava